Cary Street Partners Investment Advisory LLC Buys 341 Shares of Becton, Dickinson and Company (NYSE:BDX)

Cary Street Partners Investment Advisory LLC lifted its stake in Becton, Dickinson and Company (NYSE:BDX) by 12.7% during the second quarter, HoldingsChannel reports. The firm owned 3,032 shares of the medical instruments supplier’s stock after purchasing an additional 341 shares during the period. Cary Street Partners Investment Advisory LLC’s holdings in Becton, Dickinson and Company were worth $800,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in BDX. McClarren Financial Advisors Inc. grew its holdings in shares of Becton, Dickinson and Company by 4,900.0% in the second quarter. McClarren Financial Advisors Inc. now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 98 shares during the last quarter. Tucker Asset Management LLC purchased a new stake in Becton, Dickinson and Company in the first quarter worth about $37,000. Glass Jacobson Investment Advisors llc purchased a new stake in Becton, Dickinson and Company in the second quarter worth about $37,000. Altshuler Shaham Ltd purchased a new stake in Becton, Dickinson and Company in the second quarter worth about $38,000. Finally, Advisors Asset Management Inc. purchased a new stake in Becton, Dickinson and Company in the first quarter worth about $40,000. 86.72% of the stock is currently owned by institutional investors.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Richard Byrd sold 459 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $274.48, for a total transaction of $125,986.32. Following the sale, the executive vice president now owns 3,444 shares of the company’s stock, valued at approximately $945,309.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Claire Fraser sold 848 shares of Becton, Dickinson and Company stock in a transaction on Monday, August 28th. The shares were sold at an average price of $281.66, for a total value of $238,847.68. Following the sale, the director now owns 21,608 shares of the company’s stock, valued at approximately $6,086,109.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Richard Byrd sold 459 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $274.48, for a total transaction of $125,986.32. Following the completion of the sale, the executive vice president now directly owns 3,444 shares in the company, valued at approximately $945,309.12. The disclosure for this sale can be found here. Corporate insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on BDX shares. Morgan Stanley upped their price objective on shares of Becton, Dickinson and Company from $295.00 to $310.00 and gave the stock an “overweight” rating in a research note on Friday, August 4th. Piper Sandler lowered their price objective on shares of Becton, Dickinson and Company from $305.00 to $280.00 and set an “overweight” rating for the company in a research note on Friday, November 10th. Raymond James decreased their price target on shares of Becton, Dickinson and Company from $304.00 to $269.00 and set an “outperform” rating for the company in a research report on Friday, November 10th. Barclays increased their price target on shares of Becton, Dickinson and Company from $284.00 to $303.00 and gave the company an “overweight” rating in a research report on Monday, August 7th. Finally, Citigroup decreased their price target on shares of Becton, Dickinson and Company from $282.00 to $260.00 in a research report on Monday, October 2nd. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $282.38.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $233.27 on Monday. The firm has a market capitalization of $67.67 billion, a P/E ratio of 47.03, a PEG ratio of 1.88 and a beta of 0.55. The company has a quick ratio of 0.81, a current ratio of 1.31 and a debt-to-equity ratio of 0.57. The company has a 50 day moving average price of $256.46 and a 200 day moving average price of $260.56. Becton, Dickinson and Company has a 52 week low of $219.79 and a 52 week high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 9th. The medical instruments supplier reported $3.42 earnings per share for the quarter, hitting the consensus estimate of $3.42. Becton, Dickinson and Company had a net margin of 7.66% and a return on equity of 13.91%. The company had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $5.02 billion. During the same quarter in the prior year, the company earned $2.75 EPS. Becton, Dickinson and Company’s quarterly revenue was up 6.8% on a year-over-year basis. Sell-side analysts expect that Becton, Dickinson and Company will post 12.84 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be paid a dividend of $0.95 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.91. The ex-dividend date is Thursday, December 7th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.63%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 73.39%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.